Antisense therapy for cancer

Nature Reviews Cancer

Volumn 5, Issue 6, 2005, Pages 468-479

  Gleave, Martin E ^a   Monia, Brett P ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEG 35156; ANTISENSE OLIGONUCLEOTIDE; AS 750 15; CARBOPLATIN; CGP 69846A; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; FLUDARABINE; GEM 240; GEMCITABINE; GENE EXPRESSION MODULATOR 231; GTI 2501; ISIS 20408; ISIS 345794; ISIS 3521; LR 3001; LY 2181308; LY 2275796; MG 98; MITOXANTRONE; OBLIMERSEN; OGX 011; OGX 225; OGX 427; PACLITAXEL; UNCLASSIFIED DRUG;

ANEMIA; APOPTOSIS; BACKACHE; CANCER; CANCER GROWTH; CELL PROLIFERATION; CHEMICAL MODIFICATION; CLINICAL TRIAL; DEHYDRATION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

APOPTOSIS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; ONCOGENES; UP-REGULATION;

EID: 20344371233     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1631     Document Type: Review

References (166)

1. Zamecnik, P. C. & Stephenson, M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA 75, 280-284 (1978). First report on the use of antisense oligodeoxynucleotides to suppress gene activity in cell culture.
2. Gleave, M., Miyake, H., Zangemeister-Wittke, U. & Jansen, B. Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev. 21, 79-92 (2002).
3. Dean, N. M. & Bennett, C. F. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 22, 9087-9096 (2003).
4. Orr, R. M. & Monia, B. P. Antisense therapy for cancer. Investig. Drugs 1, 199-205 (1998).
5. Croke, S. T. Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev. 8, 133-134 (1998).
6. Wu, H. et al. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. 279, 17181-17189 (2004).
7. Galarneau, A., Min, K. L., Mangos, M. M. & Damha, M. J. Assay for evaluating ribonuclease H-mediated degradation of RNA-antisense oligonucleotide duplexes. Methods Mol. Biol. 288, 65-80 (2005).
8. Carpentier, A. F., Chen, L., Maltonti, F. & Delattre, J. Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res. 59, 5429-5432 (1999).
9. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998). First report on the use of double-stranded siRNA duplexes to suppress gene activity in animal cells.
10. Matzke, M. A. & Birchler, J. A. RNAi-mediated pathways in the nucleus. Nature Rev. Genet. 6, 24-35 (2005).
11. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified SiRNAs. Nature 432, 173-178 (2004). The first demonstration of siRNA activity in mammals following administration through routes other than the digestive tract.
12. Monia, B. P. et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-14522 (1993). This report demonstrates that RNase H is a key terminating mechanism by which antisense drugs exert their effects on gene expression. This report also demonstrates the use of 2′-modefied chimeric antisense oligonucleotides in cells.
13. Shen, L. et al. Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo. Antisense Nucleic Acid Drug Dev. 13, 129-142(2003).
14. Tsujimoto, Y. & Croce, C. M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl Acad. Sci. USA 83, 5214-5218 (1986).
15. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124, 1-6 (1994).
16. Miyashita, T. & Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81, 151-157 (1993).
17. McDonnell, T. J. et al. Expression of the protooncogene bol-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52, 6940-6944 (1992).
18. Kyprianou, N., King, E. D., Bradbury, D. & Rhee, J. G. bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int. J. Cancer 70, 341-348 (1997).
19. Raffo, A. J. et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 55, 4438-4445 (1995).
20. Miyake, H., Tolcher, A. & Gleave, M. E. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res. 59, 4030-4034 (1999).
21. Gleave, M. et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res. 5, 2891-2898 (1999).
22. Zangemeister-Wittke, U. et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 6, 2547-2555 (2000).
23. Jansen, B. et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med. 4, 232-234 (1998).
24. Webb, A. et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349, 1137-1141 (1997). This Phase I/IIa trial is the first report of the activity of BCL2 antisense in cancer patients.
25. Waters, J. S. et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 18, 1812-1823 (2000).
26. Jansen, B. et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728-1733 (2000). This Phase I/IIa trial was the first to report reduced BCL2 protein levels in serial melanoma biopsies and higher-than-expected response rates using G3139 plus DTIC in a small cohort of patients with metastatic melanoma.
27. Rai, K. R. & Moore, J. O. Phase 3 randomized trial of fludarabine/cyclophosphamide chemotherapy with or without oblimersen sodium (Bcl-2 antisense; genasense; G3139) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 104, 100a (2004).
28. Chanan-Khan, A. Bcl-2 antisense therapy in B-cell malignancies. Blood Rev. 19, 213-221 (2005).
29. Chi, K. N. et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. 7, 3920-3927 (2001).
30. De Bono, J. S., Rowinsky, E. K. & Kuhn, J. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of bcl-2 antisense (genasense) and docetaxel (D) in hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. 20, A119 (2001).
31. Chi, K. N., Murray, R. N. & Gleave, M. E. A phase II study of oblimersen sodium (G3139) and docetaxel (D) in patients (pts) with metastatic hormone-refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 22, 393 (2003).
32. Man, Z. et al. Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. Cancer Res. 56, 1621-1628 (1996).
33. Leech, S. H. et al. Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. Int. J. Cancer 86, 570-576 (2000).
34. Simoes-Wust, A. P. et al. Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells. Int. J. Cancer 87, 582-590 (2000).
35. L in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res. 60, 6052-6060 (2000).
36. Leung, S., Miyake, H., Zellweger, T., Tolcher, A. & Gleave, M. E. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int. J. Cancer 91, 846-850 (2001).
37. L and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int. J. Cancer 86, 855-862 (2000).
38. Gautschi, O. et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J. Natl Cancer Inst. 93, 463-471 (2001).
39. Newton, A. C. Regulation of protein kinase C. Curr. Opin. Cell Biol. 9, 161-167 (1997).
40. Liu, B., Maher, R. J., Hannun, Y. A., Porter, A. T. & Honn, K. V. 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKCα. J. Natl Cancer Inst. 86, 1145-1151 (1994).
41. Ways, D. K. et al. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J. Clin. Invest. 95, 1906-1915 (1995).
42. Gill, P. K., Gescher, A. & Gant, T. W. Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes α and τ. Eur. J. Biochem. 268, 4151-4157 (2001).
43. Swannie, H. C. & Kaye, S. B. Protein kinase C inhibitors. Curr. Oncol. Rep. 4, 37-46 (2002).
44. Isonishi, S., Ohkawa, K., Tanaka, T. & Howell, S. B. Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. Br. J. Cancer 82, 34-38 (2000).
45. Shen, L., Dean, N. M. & Glazer, R. I. Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Cα antisense oligonucleotide. Mol. Pharmacol. 55, 396-402 (1999).
46. Wang, X. Y., Repasky, E. & Liu, H. T. Antisense inhibition of protein kinase Cα reverses the transformed phenotype in human lung carcinoma cells. Exp. Cell Res. 250, 253-263 (1999).
47. Dean, N. M. & McKay, R. Inhibition of protein kinase Cα expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl Acad. Sci. USA 91, 11762-11766 (1994). Demonstrated for the first time that antisense oligonucleotides can inhibit gene expression in a highly specific manner when administered parenterally to normal mice.
48. Yazaki, T. et al. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α phosphorothioate oligodeoxynucleotide. Mol. Pharmacol. 50, 236-242 (1996).
49. Geiger, T., Muller, M., Dean, N. M. & Fabbro, D. Antitumor activity of a PKC-α antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des. 13, 35-45(1998).
50. Dennis, J. U. et al. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-α. Cancer Lett. 128, 65-70 (1998).
51. Nemunaitis, J. et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-α, in patients with advanced cancer. J. Clin. Oncol. 17, 3586-3595 (1999).
52. Yuen, A. R. et al. Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. 5, 3357-3363 (1999).
53. Cunningham, C. C. et al. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 6, 1626-1631 (2000).
54. Tolcher, A. W. et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 8, 2530-2535 (2002).
55. Yuen, A. R. et al. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-α, with carboplatin and paclitaxel in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. A1234 (2001).
56. Ritch, P. et al. Phase I/II trial of ISIS 3521/LY900003, an antisense inhibitor of PKC-α, with cisplatin and gemcitabine in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 21, 309a (2002).
57. Cervellera, M. et al. Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J. Biol. Chem. 275, 21055-21060 (2000).
58. Wellmann, A. et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 96, 398-404 (2000).
59. Steinberg, J. et al. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. 3, 1707-1711 (1997).
60. Redondo, M. et al. Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. 157, 393-399 (2000).
61. Miyake, H., Gleave, M., Kamidono, S. & Hara, I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 59, 150-154 (2002).
62. Parczyk, K., Pilarsky, C., Rachel, U. & Koch-Brandt, C. Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J. Cancer Res. Clin. Oncol. 120, 186-188 (1994).
63. Calero, M. et al. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc. Res. Tech. 50, 305-315 (2000).
64. Rosenberg, M. E. & Silkensen, J. Clusterin and the kidney. Exp. Nephrol. 3, 9-14 (1995).
65. Montpetit, M. L., Lawless, K. R. & Tenniswood, M. Androgen-repressed messages in the rat ventral prostate. Prostate 8, 25-36 (1986).
66. Myake, H., Nelson, C., Rennie, P. S. & Gleave, M. E. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res. 60, 170-176 (2000). Reported that increased levels of clusterin after hormone therapy conferred therapeutic resistance, identifying clusterin for the first time as a cytoprotective protein and therapeutic target.
67. Kyprianou, N., English, H. F. & Isaacs, J. T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 50, 3748-3753 (1990).
68. Bubendorf, L. et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J. Natl Cancer Inst. 91, 1758-1764 (1999).
69. July, L. V. et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50, 179-188 (2002).
70. Koch-Brandt, C. & Morgans, C. Clusterin: a role in cell survival in the face of apoptosis? Prog. Mol. Subcell. Biol. 16, 130-149 (1996).
71. Wilson, M. R. & Easterbrook-Smith, S. B. Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. 25, 95-98 (2000).
72. Michel, D., Chatelain, G., North, S. & Brun, G. Stress-induced transcription of the clusterin/apoJ gene. Biochem. J. 328, 45-50 (1997).
73. Humphreys, D. T., Carver, J. A., Easterbrook-Smith, S. B. & Wilson, M. R. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J. Biol. Chem. 274, 6875-6881 (1999).
74. Sansibar, J. A. et al. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res. 55, 2431-2437 (1995).
75. Zellweger, T. et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin. Cancer Res. 8, 3276-3284 (2002).
76. Miyake, H., Chi, K. N. & Gleave, M. E. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 6, 1655-1663 (2000).
77. Zellweger, T. et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J. Phamacol. Exp. Ther. 298, 934-940 (2001). A preclinical pharmacology paper that demonstrated that tissue half-life and target suppression was superior using a second-generation 2′-MOE OGX-011 compared to unmodified phosphorthioate ASO. These data provided the preclinical proof of principle to proceed into human trials using OGX-011.
78. July, L. V. et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther. 3, 223-232 (2004).
79. Zellweger, T. et al. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3, 360-367 (2001).
80. Miyake, H., Hara, I., Kamidono, S. & Gleave, M. E. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res. 7, 4245-4252 (2001).
81. Biroccio, A., D'Angelo, C., Gleave, M. & Gonos, E. S. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to trastuzumab. J. Cell Physiol. 31 Jan 2005 (doi:10.1002/jcp.20295).
82. Trougakos, I. P., So, A., Jansen, B., Gleave, M. E. & Gonos, E. S. Silencing expression of the clusterin/ apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 64, 1834-1842 (2004).
83. Chi, K. et al. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2′methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. J. Clin. Oncol. 22, 3033 (2004).
84. Li, F. et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580-584 (1998).
85. Schimmer, A. D. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 64, 7183-7190 (2004).
86. Okada, H. & Mak, T. W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nature Rev. Cancer 4, 592-603 (2004).
87. LaCasse, E. C., Baird, S., Korneluk, R. G. & MacKenzie, A. E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17, 3247-3259 (1998).
88. Ambrosini, G., Adida, C. & Altieri, D. C. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3, 917-921 (1997).
89. Tamm, I. et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315-5320 (1998).
90. Lu, C. D., Altieri, D. C. & Tanigawa, N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 58, 1808-1812 (1998).
91. Lal, A. et al. A public database for gene expression in human cancers. Cancer Res. 59, 5403-5407 (1999).
92. Altieri, D. C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22, 8581-8589 (2003).
93. Li, F. et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nature Cell Biol. 1, 461-466 (1999).
94. Chen, J. et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2, 235-241 (2000).
95. Ansell, S. M. et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lyrnphoma. Leukemia 18, 616-623 (2004).
96. Deveraux, Q. L., Takahashi, R., Salvesen, G. S. & Reed, J. C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388, 300-304 (1997).
97. Silke, J. et al. The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites. J. Cell Biol. 157, 115-124 (2002).
98. Salvesen, G. S. & Duckett, C. S. IAP proteins: blocking the road to death's door. Nature Rev. Mol. Cell Biol. 3, 401-410 (2002).
99. Hu, Y. et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin. Cancer Res. 9, 2826-2836 (2003).
100. Sasaki, H., Sheng, Y., Kotsuji, F. & Tsang, B. K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 60, 5659-5666 (2000).
101. Darnell, J. E. Jr., Kerr, I. M. & Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421 (1994).
102. Yu, C. L. et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269, 81-83 (1995).
103. Yu, H. & Jove, R. The STATs of cancer - new molecular targets come of age. Nature Rev. Cancer 4, 97-105 (2004).
104. Buettner, R., Mora, L. B. & Jove, R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8, 945-954 (2002).
105. Mora, L. B. et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62, 6659-6666 (2002).
106. Cheng, F. et al. A critical role for Stat3 signaling in immune tolerance. Immunity 19, 425-436 (2003).
107. Epling-Burnette, P. K. et al. Inhibitbn of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 107, 351-362 (2001).
108. Turkson, J. & Jove, R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19, 6613-6626 (2000).
109. Garrido, C. et al. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2, 579-584 (2003).
110. Concannon, C. G., Gorman, A. M. & Samali, A. On the role of Hsp27 in regulating apoptosis. Apoptosis 8, 61-70 (2003).
111. Ciocca, D. R., Oesterreich, S., Chamness, G. C., McGuire, W. L. & Fuqua, S. A. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J. Natl Cancer Inst. 85, 1558-1570 (1993).
112. Neckers, L., Schulte, T. W. & Mimnaugh, E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 17, 361-373 (1999).
113. Ramanathan, R. K., Trump, D. L. & Eiseman, J. L. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of weekly 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced tumors. J. Clin. Oncol. 22, 3031 (2004).
114. Liang, P. & MacRae, T. H. Molecular chaperones and the cytoskeleton. J. Cell Sci. 110, 1431-1440 (1997).
115. Parcellier, A., Gurbuxani, S., Schmitt, E., Solary, E. & Garrido, C. Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem. Biophys. Res. Commun. 304, 505-512 (2003).
116. Conroy, S. E. & Latchman, D. S. Do heat shock proteins have a role in breast cancer? Br. J. Cancer 74, 717-721 (1996).
117. Arts, H. J. et al. Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int. J. Cancer 64, 234-238 (1999).
118. Zhang, R., Tremblay, T. L., McDermid, A., Thibault, P. & Stanimirovic, D. Identification of deferentially expressed proteins in human glioblastoma cell lines and tumors. Glia 42, 194-208 (2003).
119. Cornford, P. A. et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 60, 7099-7105 (2000).
120. Bruey, J. M. et al. Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 19, 4855-4863 (2000).
121. Rocchi, P. et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 64, 6595-6602 (2004).
122. Garrido, C. et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res. 57, 2661-2667 (1997).
123. Vargas-Roig, L. M., Gago, F. E., Tello, O., Aznar, J. C. & Ciocca, D. R. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int. J. Cancer 79, 468-475 (1998).
124. Garrido, C. et al. HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J. 13, 2061-2070 (1999).
125. Paul, C. et al. Hsp27 as a negative regulator of cytochrome C release. Mol. Cell. Biol. 22, 816-834 (2002).
126. Concannon, C. G., Orrenius, S. & Samali, A. Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c. Gene Expr. 9, 195-201 (2001).
127. Ho, S. P. et al. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nature Biotechnol. 16, 59-63 (1998).
128. Matveeva, O., Felden, B., Audlin, S., Gesteland, R. F. & Atkins, J. F. A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures. Nucleic Acids Res. 25, 5010-5016 (1997).
129. Stull, R. A., Taylor, L. A. SSzoka, F. C. Jr. Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices. Nucleic Acids Res. 20, 3501-3508 (1992).
130. Butler, M. et al. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 51, 1028-1034 (2002).
131. Geary, R. S. et al. Pharmacokinetic properties of 2′-O-(2- methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296, 890-897 (2001). Describes the pharmacokinetic attributes of second-generation 2′-MOE antisense oligonucleotides in animals.
132. Henry, S. P., Geary, R. S., Yu, R. & Levin, A. A. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr. Opin. Investig. Drugs 2, 1444-1449 (2001).
133. Henry, S. P., Monteith, D., Bennett, F. & Levin, A. A. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-α and C-raf kinase. Anticancer Drug Des. 12, 409-420 (1997).
134. Levin, A. A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84 (1999).
135. Henry, S. P., Monteith, D. & Levin, A. A. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. 12, 395-408 (1997).
136. Geary, R. S. et al. Pharmacokinetics of a tumor necrosis factor-α phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab. Dispos. 31, 1419-1428 (2003).
137. Cook, P. Second generation antisense oligonucleotides: 2′-modifications. Annu. Rep. Med. Chem. 33, 313 (1998).
138. Vester, B. & Wengel, J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 43, 13233-13241 (2004).
139. Pollak, M. N., Schernhammer, E. S. & Hankinson, S. E. Insulin-like growth factors and neoplasia. Nature Rev. Cancer 4, 505-518 (2004). Excellent contemporary review on the IGF1 axis in cancer.
140. Jones, J. I. & Clemmons, D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16, 3-34 (1995).
141. Myake, H., Nelson, C., Rennie, P. S. & Gleave, M. E. Overexpresston of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 141, 2257-2265 (2000).
142. Miyake, H., Pollak, M. & Gleave, M. E. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res. 60, 3058-3064 (2000).
143. Kiyama, S. et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res. 83, 3575-3584 (2003).
144. Bae, J., Leo, C. P., Hsu, S. Y. & Hsueh, A. J. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J. Biol. Chem. 275, 25255-25261 (2000).
145. Akgul, C., Turner, P. C., White, M. R. & Edwards, S. W. Functional analysis of the human MCL-1 gene. Cell Mol. Life Sci. 57, 684-691 (2000).
146. L is an essential survival protein of human myeloma cells. Blood 100, 194-199 (2002).
147. Zhou, P., Qian, L., Kozopas, K. M. & Craig, R. W. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89, 630-643 (1997).
148. Miyamoto, Y. et al. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology 56, 73-82 (1999).
149. Chung, T. K. et al. Expression of apoptotic regulators and their significance in cervical cancer. Cancer Lett. 180, 63-68 (2002).
150. Cho-Vega, J. H. et al. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum. Pathol. 35, 1095-1100 (2004)
151. Heere-Ress, E. et al. Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int. J. Cancer 99, 29-34 (2002).
152. Thallinger, C. et al. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin. Cancer Res. 10, 4185-4191 (2004).
153. L antisense oligonucleotides radiosensitise colon cancer cells. Br. J. Cancer 89, 1352-1357 (2003).
154. Sigalas, I., Calvert, A. H., Anderson, J. J., Neal, D. E. & Lunec, J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature Med. 2, 912-917 (1996).
155. Wang, H., Yu, D., Agrawal, S. & Zhang, R. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 54, 194-205 (2003).
156. Zhang, Z., Li, M., Wang, H., Agrawal, S. & Zhang, R. Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl Acad. Sci. USA 100, 11636-11641 (2003).
157. Adjei, A. A. et al. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin. Cancer Res. 9, 115-123 (2003).
158. Davis, A. J. et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest. New Drugs 21, 85-97 (2003).
159. deFabritiis, P. et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 91, 3156-3162 (1998).
160. Nylandsted, J. et al. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc. Natl Acad. Sci. USA 97, 7871-7876 (2000).
161. Ratajczak, M. Z. et al. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 79, 1956-1961 (1992).
162. Tortora, G. et al. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin. Cancer Res. 6, 2506-2512 (2000).
163. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M. & Fabbro, D. Antitumor activity of a osphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2, 668-675 (1996).
164. Stevenson, J. P. et al. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol. 17, 2227-2236 (1999).
165. Bishop, M. R. et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. 14, 1320-1326 (1996).
166. Eder, I. E. et al. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther. 9, 117-125 (2002).